bio.logis

What bio.logis does

bio.logis digital health GmbH is a Frankfurt-based software company, founded in November 2013 as a spin-off from a genetic-diagnostic laboratory, that builds the Genetic Information Management System (GIMS), a modular platform for automated interpretation, reporting, and delivery of human genetic data into clinical workflows. The platform combines a Content Management System with a rule engine that maps genetic variant data (CSV/VCF input from any sequencing or genotyping platform) against the KNMP-licensed G-Standaard drug database to produce validated pharmacogenetic dosing recommendations across 13 genes, 49 variants, and 80 active ingredients. The Diagnostic Report Module (CE-marked Class I medical device) generates clinical reports with up to 95% claimed time and cost savings, with results delivered through a patient web portal, the pharma.sensor mobile app (iOS and Android), and a printable Medication Safety Card with QR/barcode access for emergency use. Product variants include GIMS.pharma for pharmacogenomics and DNAwiz for broader variant classification.

The company serves genetic diagnostic laboratories and hospitals across Europe, with named implementations at seven European university hospitals through the Horizon 2020-funded U-PGx consortium and additional customers in Germany, Austria, Switzerland, Luxembourg, and Belgium. bio.logis operates a hybrid SaaS revenue model comprising annual subscription fees (operational fees billed in advance), one-time implementation services, usage-based per-analysis credits valid for 12 months, and custom development charges; pricing is not publicly disclosed. Distribution combines direct enterprise sales with a channel partnership through PGS.Holland BV covering Benelux, Scandinavia, and the UK. The Diagnostic Report Module is hosted on Deutsche Telekom data centers in Germany, with GDPR-compliant pseudonymized data processing. The company is founder-led (Prof. Daniela Steinberger) following a 2021 management buyout and NGO-style restructuring, with no disclosed institutional venture backing; total disclosed funding to date is €2.4 million via the 2016 EU Horizon 2020 grant.

Name

bio.logis

Legal name

bio.logis digital health GmbH

Website

https://biologis.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

bio.logis builds GIMS, a CE-marked Class I software platform that automates the interpretation, reporting, and clinical delivery of genetic and pharmacogenomic data for European diagnostic laboratories, hospitals, and physicians.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Pharmacogenomics software
• Clinical decision support
• Genetic diagnostic reports
• Laboratory information systems
• Precision medicine platform

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Subscription (Operational Fees): Annual subscription fees for access to GIMS platform and functionalities. Due in advance for 12 months starting calendar month following Go-Live. Includes system releases, updates, security updates, and content updates.
2. Implementation Services: One-time implementation and set-up fees for customizing and deploying GIMS at customer sites. Includes testing, training, and Go-Live support.
3. Per-Analysis Credits: Credits purchased in advance for production of patient-specific results and Medication Safety Cards. Valid for 12 months after purchase. One credit charged per analysis per patient.
4. Custom Development: Additional fees for customer-specific feature requirements beyond planned software development.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

bio.logis provides the Genetic Information Management System (GIMS), a software platform that automates interpretation, reporting, and delivery of genetic data for clinical use. It offers specialized variants including GIMS.pharma for pharmacogenomics-based medication recommendations and DNAwiz for variant classification, with results delivered via web portal and the pharma.sensor mobile app to laboratories, hospitals, and patients.

Product overview

bio.logis offers the Genetic Information Management System (GIMS), a modular software platform for automated genetic data interpretation, reporting, and delivery. The core GIMS platform provides workflow management, knowledge management, and clinical decision support, with specialized product variants including GIMS.pharma for pharmacogenomics and DNAwiz for variant classification. Key modules include the Diagnostic Report Module (DRM) for automated report generation, Report Layout Engine (RLE) for document formatting, and a Content Management System with rule engine for pharmacogenetic recommendations. Results are delivered via a patient web portal and the pharma.sensor mobile app, with a Medication Safety Card feature for emergency access. The system is CE-marked as a Class I medical device and hosted on Deutsche Telekom infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• GIMS (Genetic Information Management System): Core IT platform for automated interpretation, reporting and delivery of genetic data for human genetics diagnostics.
• GIMS.pharma
• DNAwiz
• pharma.sensor

Products and services

• GIMS (Genetic Information Management System) Central software platform enabling automated interpretation, reporting, and digital delivery of genetic data for clinical practice, providing workflow, collaboration, knowledge management, and clinical decision support for human genetics laboratories and healthcare providers.
• GIMS.pharma Pharmacogenomics software solution that processes pharmacogenetic diagnostics and translates laboratory result data into validated clinical recommendations for personalized medication, with delivery via web portal and mobile app.
• DNAwiz Clinical decision-making solution for genetic diagnostics providing structured step-by-step workflows for variant classification, clinical interpretation, and recommendation in genetic laboratories.
• pharma.sensor App Mobile application for iOS and Android that enables patients and physicians to check drug compatibility based on personal DNA variants via drug name entry or barcode scanning, providing Smart Functions for clinical context.

Quantifiable outcome

• 30% reduction in serious adverse drug reactions when medication is genetically-adjusted using GIMS platform
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered strategic, core and minor.

• in silico MedTech Innovation NetworkstrategicStrategic or Co-development Partner · 10 January 2025Innovation network funded by BMWK (German Federal Ministry for Economic Affairs and Climate Action) under ZIM program. 23 network partners from SMEs and research institutions developing digital procedures for medical technology and healthcare using AI, data management, language/gesture control, personalized medicine, simulation and XR technologies.
• EuformaticsstrategicTechnology or Integration · 17 February 2020Partnership to enable laboratories using Euformatics' tertiary analysis platform to provide patients with pharmacogenomic dosing recommendations. Integration provides seamless workflow for NGS diagnostics.
• KNMP (Royal Dutch Pharmacists Association) / Z-IndexcoreStrategic or Co-development Partner · 17 May 2018License agreement enabling GIMS to directly retrieve G-Standaard drug database dosage recommendations based on pharmacogenetic insights. KNMP's Dutch Pharmacogenetics Working Group provides regular updates to recommendations covering 13 genes, 49 variants, and 80 active ingredients. Bio.logis has collaborated with KNMP since 2016 within the EU-funded U-PGx project.
• Robert-Bosch-Krankenhaus (RBK) Stuttgart / Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP)coreStrategic or Co-development Partner · 20 March 2018Implementation of GIMS at RBK hospital and IKP institute. GIMS integrated with hospital information system and IKP's genotyping platform. First major German hospital implementation for pharmacogenetics integration into clinical practice.
• Medical University of Vienna (MUW)coreStrategic or Co-development Partner · 12 March 2018Implementation of GIMS within U-PGx EU project. MUW uses Diagnostic Report Module combined with QR-based safety code card (developed by MUW's Prof. Matthias Samwald) for patient access to pharmacogenetic results.
• PGS.Holland BVcoreChannel Partner/ Reseller/ Distributor · 8 December 2017Distribution collaboration to market GIMS in Benelux countries, Scandinavia, and UK. PGS.Holland concentrates on marketing GIMS.pharma as a pharmacogenetic end-to-end product for easy integration with diagnostic laboratory systems.
• Laboratoires Réunis GroupstrategicStrategic or Co-development Partner · 16 November 2017One of largest private laboratories in Luxembourg uses GIMS to automate creation of complex genetic diagnostic reports. Initial focus on Diagnostic Report Module for efficient report generation with standardization.
• U-PGx Consortium (Horizon 2020)coreStrategic or Co-development Partner · 4 April 2016EU-funded Ubiquitous Pharmacogenomics consortium (Grant No. 668353) implementing pharmacogenetics in clinical practice across Europe. Consortium includes: LUMC, Uppsala University, University of Liverpool, Karolinska Institutet, UMC Utrecht, Medical University Vienna, University of Patras, University of Toulouse, University of Ljubljana, and others. Bio.logis received €2.4M EU funding for implementation.
• Global Alliance for Genomics & Health (GA4GH)strategicStrategic or Co-development PartnerMembership in international alliance working to enable responsible sharing of genomic and health-related data.
• EurA AGminorOthersNetwork management organization for in silico MedTech innovation network. Led by Dr. Manfred Kauer and Dr. Franziska Mäckle.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Illumina: Illumina is the dominant sequencing platform provider and offers DRAGEN secondary analysis and BaseSpace informatics tools. As a broad incumbent, it competes with bio.logis in genomic data interpretation, particularly for NGS-based diagnostics, but as part of a much larger sequencing hardware/software portfolio.
• Invitae: Invitae (which acquired Diploid) is a major genetic testing and clinical genomics company with a broad hereditary disease testing menu and clinical interpretation capabilities. It represents a broader incumbent competing with bio.logis across the genomics interpretation and reporting value chain.
• Agilent Alissa: Agilent's Alissa Interpret is a clinical genomics interpretation platform for hereditary disease and oncology testing. As part of Agilent's broader diagnostics portfolio, it competes with bio.logis's DNAwiz in variant classification and clinical reporting for diagnostic laboratories.

Direct peers

• Fabric Genomics: Fabric Genomics offers AI-driven clinical genomic interpretation software for rare disease and hereditary cancer diagnostics. It is comparable to bio.logis in providing automated interpretation, variant classification, and clinical reporting for diagnostic laboratories.
• SOPHiA Genetics: SOPHiA Genetics offers a cloud-based genomic data analysis platform used by hospitals and laboratories for clinical genomics interpretation. It is a direct competitor to bio.logis's GIMS platform in the genomics clinical decision support space, serving similar hospital and lab customers across Europe and globally.
• PierianDx: PierianDx (now part of Euformatics) provides a clinical genomics decision support platform for hereditary disease diagnostics and oncology. It is a direct peer to bio.logis in the clinical genomics interpretation and reporting market, particularly for hospital and lab customers.
• Congenica: Congenica provides a clinical genomics interpretation platform used by diagnostic laboratories and hospitals. It competes directly with bio.logis's GIMS and DNAwiz products in the automated genomic variant interpretation and clinical reporting market.

Emerging players

• Genoox: Genoox provides a cloud-based platform for genomic data analysis and clinical interpretation. It overlaps with bio.logis in serving clinical labs with automated variant interpretation, though it focuses more broadly on NGS workflows including hereditary disease and oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bio-logis-gmbh
• Xx.com/bio_logis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about bio.logis